Obesity Clinical Trial
Official title:
Using the Sequential Multiple Assignment Randomized Trial Experimental Approach to Develop an Adaptive Lifestyle Intervention Program in Family Medicine Clinics
Verified date | June 2022 |
Source | University of Alabama at Birmingham |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to investigate the feasibility of conducting a multicomponent lifestyle intervention research study within the UAB Family Medicine Clinic at Highlands and to obtain preliminary data on the effectiveness of the adaptive treatment strategies being investigated to produce improvements in insulin resistance. This study is a Sequential Multiple Assignment Randomized Trial (SMART) with initial randomization groups of individualized nutrition counseling vs. individualized exercise counseling. Note that these initial nutrition or exercise interventions are NOT intended to produce significant weight loss. Participants that do not sufficiently improve their insulin resistance score after 8 weeks will be re-randomized to 2nd stage interventions of either receiving dietary counseling for weight loss or receiving a prescription for metformin. We will collect data on the effectiveness of the intervention to improve insulin resistance/metabolic health in the family medicine clinic as well as potential predictors or moderators of treatment success.
Status | Completed |
Enrollment | 40 |
Est. completion date | June 3, 2022 |
Est. primary completion date | June 3, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Male or female - Any race or ethnicity - BMI >27 kg/m2 - Presence of 1 or more mild-to-moderate obesity-associated metabolic complications (i.e., Stage 1 Obesity) - Prediabetes, type 2 diabetes (see exclusion criteria for additional details), metabolic syndrome, dyslipidemia, hypertension, non-alcoholic fatty liver disease - Stable medication type and dosage for =3 months Exclusion Criteria: - If type 2 diabetes, - Currently prescribed metformin or prescribed within previous 3 months - HbA1c concentration of >12% - Using exogenous insulin - Pregnant or lactating within the past 6 months or trying to become pregnant - Prescription for weight loss medications within the past 3 months - Severe obesity-related complications that require immediate and more intensive clinical therapy (e.g., pharmacotherapy and/or bariatric surgery) as determined by study physician and/or referring practitioner at UAB Family Medicine Clinic. - History of kidney disease that may increase the risk of lactic acidosis with metformin. - Currently prescribed the following medications that may increase the risk of lactic acidosis with metformin: acetazolamide (Diamox), dichlorphenamide (Keveyis), methazolamide, topiramate (Topamax, in Qsymia), or zonisamide (Zonegran). - Does not have a life-sustaining medical implant such as a pacemaker. |
Country | Name | City | State |
---|---|---|---|
United States | UAB Highlands Family and Community Medicine Clinic | Birmingham | Alabama |
Lead Sponsor | Collaborator |
---|---|
University of Alabama at Birmingham |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rates of recruitment and retention | Number of participants recruited and retained in intervention | Baseline | |
Primary | Rates of recruitment and retention | Number of participants recruited and retained in intervention | Month 2 | |
Primary | Rates of recruitment and retention | Number of participants recruited and retained in intervention | Month 6 | |
Primary | Family medicine clinician referral rates | Baseline | ||
Primary | Family medicine clinician referral rates | Month 2 | ||
Primary | Family medicine clinician referral rates | Month 6 | ||
Primary | Number of counseling sessions attended | Attendance to Zoom meetings | Month 2 | |
Primary | Number of counseling sessions attended | Attendance to Zoom meetings | Month 6 | |
Primary | Frequency of metformin adherence (as applicable) | Number of times metformin was taken as prescribed | Month 2 | |
Primary | Frequency of metformin adherence (as applicable) | Number of times metformin was taken as prescribed | Month 6 | |
Primary | Intervention preference | Preference is determined by the Intervention Preference Questionnaire, using a 5-point Likert Scale for preference among study treatment arms. Scale includes options for "strong," "slight," or "no" preference for a given treatment component. | Baseline | |
Primary | Intervention preference | Preference is determined by the Intervention Preference Questionnaire, using a 5-point Likert Scale for preference among study treatment arms. Scale includes options for "strong," "slight," or "no" preference for a given treatment component. | Month 2 | |
Primary | Intervention preference | Preference is determined by the Intervention Preference Questionnaire, using a 5-point Likert Scale for preference among study treatment arms. Scale includes options for "strong," "slight," or "no" preference for a given treatment component. | Month 6 | |
Primary | Treatment credibility | Assessment of participants' perception of treatment success using the Credibility/Expectancy Questionnaire with a 9-point Likert scale, ranging from "not at all" (1) to "very" (9) for several descriptors (e.g., "useful," "logical.") | Baseline | |
Primary | Treatment credibility | Assessment of participants' perception of treatment success using the Credibility/Expectancy Questionnaire with a 9-point Likert scale, ranging from "not at all" (1) to "very" (9) for several descriptors (e.g., "useful," "logical.") | Month 2 | |
Primary | Treatment credibility | Assessment of participants' perception of treatment success using the Credibility/Expectancy Questionnaire with a 9-point Likert scale, ranging from "not at all" (1) to "very" (9) for several descriptors (e.g., "useful," "logical.") | Month 6 | |
Secondary | Changes in body weight | Baseline to Months 2 and 6 | ||
Secondary | Changes in body composition (fat and lean mass) | Fat mass and lean mass via bioelectrical impedance analysis | Baseline to Months 2 and 6 | |
Secondary | Changes in glucose | Serum glucose will be measured in a fasted state | Baseline to Months 2 and 6 | |
Secondary | Changes in insulin | Serum insulin will be measured in a fasted state | Baseline to Months 2 and 6 | |
Secondary | Changes in glycosylated hemoglobin (hemoglobin A1C) | Percentage (%) glycated hemoglobin as a measure of long-term blood glucose control | Baseline to Months 2 and 6 | |
Secondary | Changes in lipids | Fasting serum concentrations of total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides | Baseline to Months 2 and 6 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |